open access

Vol 87, No 5 (2016)
Research paper
Published online: 2016-06-02
Get Citation

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Mehmet Keçecioğlu, Aytekin Tokmak, Tuğban S. Keçecioğlu, Burak Akselim, Burcu K. Karakaya, Yasemin Taşçı
DOI: 10.5603/GP.2016.0010
·
Pubmed: 27304657
·
Ginekol Pol 2016;87(5):390-394.

open access

Vol 87, No 5 (2016)
ORIGINAL PAPERS Obstetrics
Published online: 2016-06-02

Abstract

Objectives: The effect of exogenous progesterone on fetal nuchal translucency (NT) has been proposed recently. In this study, we aimed to compare the thickness of NT of patients receiving and not receiving progesterone for threatened miscarriage.

Material and methods: This study was designed as a retrospective comparative study. Ninety five women treated with progesterone constituted the study group whereas 97 women who were not treated with progesterone constituted the control group. An ultrasonographic examination was performed on all of the women to measure NT. All patients were treated with oral micronized progesterone in the study group. The main parameters recorded for each woman were; age, body mass index (BMI), obstetrical characteristics, and gestational age at first examination, treatment duration of progesterone therapy, and results of combined and triple tests.

Results: A total of 192 pregnant women with threatened miscarriage were included in this study. The mean NT thickness was statistically significantly higher in the study group (p < 0.001), and mean serum level of human chorionic gonadotropin (hCG) was also higher in this group (p < 0.05). There was no statistically significant difference between groups in terms of age, BMI, and gestational age at first examination. ROC curve analysis demonstrated that only increased NT (area under the curve: 0.634, p = 0.005, 95% CI: 0.541–0.727) was a discriminative factor for women receiving progesterone for threatened miscarriage. Also there was a positive correlation between NT and treatment duration (r = 0.269; p < 0.001).

Conclusions: We think that oral progesterone therapy may increase NT depending on treatment duration without causing abnormal prenatal screening test results.

Abstract

Objectives: The effect of exogenous progesterone on fetal nuchal translucency (NT) has been proposed recently. In this study, we aimed to compare the thickness of NT of patients receiving and not receiving progesterone for threatened miscarriage.

Material and methods: This study was designed as a retrospective comparative study. Ninety five women treated with progesterone constituted the study group whereas 97 women who were not treated with progesterone constituted the control group. An ultrasonographic examination was performed on all of the women to measure NT. All patients were treated with oral micronized progesterone in the study group. The main parameters recorded for each woman were; age, body mass index (BMI), obstetrical characteristics, and gestational age at first examination, treatment duration of progesterone therapy, and results of combined and triple tests.

Results: A total of 192 pregnant women with threatened miscarriage were included in this study. The mean NT thickness was statistically significantly higher in the study group (p < 0.001), and mean serum level of human chorionic gonadotropin (hCG) was also higher in this group (p < 0.05). There was no statistically significant difference between groups in terms of age, BMI, and gestational age at first examination. ROC curve analysis demonstrated that only increased NT (area under the curve: 0.634, p = 0.005, 95% CI: 0.541–0.727) was a discriminative factor for women receiving progesterone for threatened miscarriage. Also there was a positive correlation between NT and treatment duration (r = 0.269; p < 0.001).

Conclusions: We think that oral progesterone therapy may increase NT depending on treatment duration without causing abnormal prenatal screening test results.

Get Citation

Keywords

nuchal translucency, prenatal screening tests, progesterone therapy, threatened miscarriage

About this article
Title

Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?

Journal

Ginekologia Polska

Issue

Vol 87, No 5 (2016)

Article type

Research paper

Pages

390-394

Published online

2016-06-02

DOI

10.5603/GP.2016.0010

Pubmed

27304657

Bibliographic record

Ginekol Pol 2016;87(5):390-394.

Keywords

nuchal translucency
prenatal screening tests
progesterone therapy
threatened miscarriage

Authors

Mehmet Keçecioğlu
Aytekin Tokmak
Tuğban S. Keçecioğlu
Burak Akselim
Burcu K. Karakaya
Yasemin Taşçı

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl